These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 9747102)

  • 21. [Economic evaluation on strategy for preventing mother-to-child transmission of hepatitis B in Zhejiang Province].
    Zeng YB; Luo ML; He HQ; Deng X; Xie SY; Fang Y
    Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Jul; 53(7):706-712. PubMed ID: 31288342
    [No Abstract]   [Full Text] [Related]  

  • 22. Acute hepatitis B 14 years after the implementation of universal vaccination in Italy: areas of improvement and emerging challenges.
    Mele A; Tosti ME; Mariano A; Pizzuti R; Ferro A; Borrini B; Zotti C; Lopalco P; Curtale F; Balocchini E; Spada E;
    Clin Infect Dis; 2008 Mar; 46(6):868-75. PubMed ID: 18269332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis.
    Beutels P; Edmunds WJ; Antoñanzas F; De Wit GA; Evans D; Feilden R; Fendrick AM; Ginsberg GM; Glick HA; Mast E; Péchevis M; Van Doorslaer EK; van Hout BA;
    Pharmacoeconomics; 2002; 20(1):1-7. PubMed ID: 11817988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Should Canada and the United States universally vaccinate infants against hepatitis B? A cost-effectiveness analysis.
    Krahn M; Detsky AS
    Med Decis Making; 1993; 13(1):4-20. PubMed ID: 8433635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Cost-effectiveness analysis of different alternatives of universal vaccination against hepatitis B in the region of Murcia].
    Guillén Grima F; Espín Ríos MI
    Med Clin (Barc); 1995 Feb; 104(4):130-6. PubMed ID: 7898156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and economic impact of a combination Haemophilus influenzae and Hepatitis B vaccine: estimating cost-effectiveness using decision analysis.
    Fendrick AM; Lee JH; LaBarge C; Glick HA
    Arch Pediatr Adolesc Med; 1999 Feb; 153(2):126-36. PubMed ID: 9988242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serological and molecular epidemiological outcomes after two decades of universal infant hepatitis B virus (HBV) vaccination in Nunavut, Canada.
    Huynh C; Minuk GY; Uhanova J; Baikie M; Wong T; Osiowy C
    Vaccine; 2017 Aug; 35(35 Pt B):4515-4522. PubMed ID: 28736196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents.
    Mast EE; Margolis HS; Fiore AE; Brink EW; Goldstein ST; Wang SA; Moyer LA; Bell BP; Alter MJ;
    MMWR Recomm Rep; 2005 Dec; 54(RR-16):1-31. PubMed ID: 16371945
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Long-term efficacy of infant hepatitis B immunization program].
    Gong J; Li RC; Yang JY; Li YP; Chen XR; Xu ZY; Liu CB; Cao HL; Zhao K; Ni DM
    Zhonghua Gan Zang Bing Za Zhi; 2003 Apr; 11(4):203-5. PubMed ID: 12716514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic analysis of promotion of hepatitis B vaccinations among Vietnamese-American children and adolescents in Houston and Dallas.
    Zhou F; Euler GL; McPhee SJ; Nguyen T; Lam T; Wong C; Mock J
    Pediatrics; 2003 Jun; 111(6 Pt 1):1289-96. PubMed ID: 12777543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Confusing games of public insurance with hepatitis B vaccinations. Interview by Dr. rer. nat. Anita Schweiger].
    Eichhorn R
    Fortschr Med; 1997 Apr; 115(10):41. PubMed ID: 9206686
    [No Abstract]   [Full Text] [Related]  

  • 32. Cost-benefit analysis of the introduction of mass vaccination against hepatitis B in Italy.
    Demicheli V; Jefferson TO
    J Public Health Med; 1992 Dec; 14(4):367-75. PubMed ID: 1489561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [VACCINATION AGAINST HEPATITIS B: WHAT'S UP?].
    Launay O; Floret D
    Rev Prat; 2015 Sep; 65(7):953-61. PubMed ID: 26619734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Vaccination against hepatitis B and epidemiological situation of this disease in European countries in the years 1990-2001].
    Magdzik W
    Przegl Epidemiol; 2006; 60(2):179-84. PubMed ID: 16964667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-benefit analysis of the Polish hepatitis B prevention programme.
    Wiewióra-Pilecka D
    Vaccine; 2000 Feb; 18 Suppl 1():S52-4. PubMed ID: 10683548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An economic evaluation of universal vaccination against hepatitis B virus.
    Fenn P; Gray A; McGuire A
    J Infect; 1996 May; 32(3):197-204. PubMed ID: 8793708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Study on the cost-effectiveness, benefit and utility analysis on the infant inoculation hepatitis B vaccine in Shanghai].
    Wu GY; Gong YL; Yu SL; Shao RT; Qin HJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Jun; 25(6):474-8. PubMed ID: 15231120
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Benefits of early hepatitis B immunization programs for newborns and infants.
    Van Herck K; Van Damme P
    Pediatr Infect Dis J; 2008 Oct; 27(10):861-9. PubMed ID: 18776823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness and impact of hepatitis B virus vaccination of children with at least one parent born in a hepatitis B virus endemic country: an early assessment.
    Hontelez JA; Hahné S; Koedijk FH; de Melker HE
    J Epidemiol Community Health; 2010 Oct; 64(10):890-4. PubMed ID: 19822551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surveillance for acute viral hepatitis - United States, 2007.
    Daniels D; Grytdal S; Wasley A;
    MMWR Surveill Summ; 2009 May; 58(3):1-27. PubMed ID: 19478727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.